Shots:

• TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2
• Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets- associated sequences and relevant data for the development and commercialization of IVD tests. In advance of exercising its option- Qiagen has the right to evaluate TScan’s discoveries
• The targeted immunodominant were identified through the T-Scan TCR/Target discovery platform enabling the mapping of the specific epitopes in SARS-CoV-2

­  Ref: Businesswire | Image: TrialSite News